Alcasol® oral solution is a combined preparation of Potassium Citrate and Citric Acid Monohydrate. Alcasol® oral solution is a sugar free, stable and pleasant-tasting oral systemic alkalinizer. Potassium Citrate is absorbed and metabolized to Potassium Bicarbonate, thus acting as a systemic alkalinizer. Alcasol® alkalinizes the urine without producing a systemic alkalosis in recommended doses. Potassium Citrate does not neutralize the gastric juice or disturb digestion.
No Data
Alcasol® is indicated in the following cases-
Route of administration: Alcasol® can be taken in oral route after meal or bedtime. Palatability is enhanced if chilled before taking.
To relieve discomfort in UTI-
Adults including the elderly and children over 6 years: 10 ml 3 times daily, diluted with 1 glass of water (250 ml) followed by additional water if desired.
Children 1-6 years: 5 ml 3 times daily, diluted with % glass of water (125 ml) followed by additional water if desired.
To prevent kidney stones, with a uricosuric agent to prevent gout and acidosis caused by kidney diseases-
Adults: 10-15 ml 4 times daily diluted with 1 glass of water (250 ml).
Pediatric. 5-10 ml 4 times daily diluted with % glass of water (125 ml).
Pregnancy: This combination should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.
Lactation: No information is available on the presence of this combination in human milk, the effects of the drug on milk production or the effects of the drug on the breastfed infant.
Use in children and adolescents
The safety and efficacy of this solution in children and adolescents have been established.
The solution should be used with caution in patients with low urinary output. It should be diluted adequately with water to minimize the possibility of gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations and preferably, to take each dose after meals. Large doses may cause hyperkalemia and alkalosis, especially in the presence of renal disease.
This solution is generally well tolerated without any unpleasant side effect when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis. Potassium intoxication causes listlessness, weakness, mental confusion, tingling of extremities and other symptoms associated with a high concentration of potassium in the serum.
This oral solution is contraindicated in patients with known hypersensitivity to potassium citrate and citric acid monohydrate or any other components of this product. It is also contraindicated in severe renal impairment with oliguria or azotemia, untreated Addison's disease, acute dehydration, severe myocardial damage and hyperkalemia from any cause.
Drug interaction with medication: Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors or cardiac glycosides may lead to toxicity.
Drug interaction with food and others: Not applicable.
The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, hyperkalemia can result. Hyperkalemia, when detected, must be treated immediately because lethal levels can be reached in a few hours. If hyperkalemia occurs, treatment measures should include the following, elimination of foods or medications containing potassium, intravenous administration of 300 to 500 ml/hr of dextrose solution (10 to 25%) containing 10 units of insulin/20 g dextrose and the use of exchange resins, hemodialysis or peritoneal dialysis.
No Data
No Data
No Data
Store in a cool (below 30°C) & dry place protected from light. Keep away from the reach of children.